Content about Company Product

Greater consumer awareness of the dangers of the sun’s harmful rays and greater product innovation are spelling growth in the sun care market. And, as the industry wades through the recently issued regulations by the Food and Drug Administration, new innovative products for both children and adults hit the pipeline, which is likely to mean further growth.


The wider availability of relaxants and perms — which largely are geared toward African-American hair — coupled with consumers seeking greater value due to a challenging economy has helped fuel sales of the niche segment.


INDIANAPOLIS — Drug maker Eli Lilly has launched what it’s calling an “umbrella” for its patient assistance programs.

Lilly subsidiary Lilly USA announced the launch of TruAssist, which comprises a website and call center for patients and healthcare providers to access information about programs the company provides to help increase access to Lilly medications. The website is at LillyTrueAssist.com, while the call center can be reached at 1-855-LLYTRUE (1-855-559-8783).

TITUSVILLE, Fla. — Infopia America last week announced that its new SmartDiabetes product line has launched in 284 Walgreens drug stores in central and northeast Florida. The central Florida Walgreens region includes stores in Jacksonville, Orlando, Lakeland, Daytona Beach and Melbourne.

AMITYVILLE, N.Y. — Sundial has announced that Walgreens has become the exclusive national drug store retail partner for its SheaMoisture hair care line and will carry the products on shelf and online, beginning April 1.

"We are very excited to launch our newest collection at Walgreens," stated Richelieu Dennis, founder and CEO of Sundial Creations, maker of SheaMoisture. "They have been a key partner in the growth of our business and we are enthusiastic about bringing organic hair care products to such a broad consumer base."

MORRISTOWN, N.J. — A subsidiary of Watson Pharmaceuticals has launched a treatment for herpes infections, the company said Monday.

Watson Labs launched famciclovir tablets in the 125-mg, 250-mg and 500-mg strengths. The drug is a generic version of Novartis’ Famvir and is used to treat cold sores and genital herpes in patients with and without HIV.

Famvir and generic versions had sales of about $197 million in 2010, according to IMS Health.

STAMFORD, Conn. — Drug maker Purdue Pharma is giving a $1 million grant to the state of Florida to help fund the state’s prescription drug monitoring program, the company said Wednesday.

Purdue said the program was designed to combat illegal diversion and abuse of prescription drugs. Purdue is the maker of OxyContin (oxycodone), an extended-release opioid painkiller that often is a target of abuse.

SUPPLIER NEWS — Juicy Fruit has expanded its sugar-free gum offerings with new mystery-flavored Juicy Secret gum. The gum builds on the 2009 launch of Juicy Fruit’s foray into sugar-free treats with its pellet gum, available in parent company Wrigley’s Big E-pak. Juicy Secret will be available in a 15-stick slim pack nationwide.

GUILFORD, Conn. — Mitchell-Vance Laboratories, which specializes in the treatment and prevention of scars, has announced the introduction of its new ScarAway scar diminishing serum.

The product is launching at Walgreens stores nationwide in April for a suggested retail price of $17.99.

ScarAway scar diminishing serum is designed to effectively shrink, flatten and fade hypertrophic (raised) and keloid scars, which may result from surgical procedures, injuries, burns, stretch marks or acne.

CLEVELAND — Highlighting lovable pairs this Valentine's Day, American Greetings has introduced Opening Acts.

Opening Acts is a collection that pairs cards with specially designed envelopes that play a song or sound when opened, offering consumers a fun and unexpected way to show the ones they love how much they care.

American Greetings' Opening Acts line is available at stores nationwide.

PITTSBURGH — Generic drug maker Mylan has entered settlements with Pfizer concerning two drugs for treating cholesterol.

Mylan announced Tuesday that it had settled patent litigation suits with Pfizer concerning Lipitor (atorvastatin calcium) and Caduet (atorvastatin calcium and amlodipine besylate).

Under the Caduet agreement, the lawsuit will be dismissed, and Mylan can launch its generic version on Nov. 30. Terms of the Lipitor agreement remain confidential.